MUMBAI (Reuters) – The U.S. healthcare regulator has found fault with quality control, training and staff hygiene at Wockhardt Ltd’s plant in Chicago, potentially adding to regulatory problems facing the Indian generic drugmaker.
The U.S. Food and Drug Administration (FDA) listed…
FDA criticizes quality control, training at Wockhardt U.S. plant
No comments:
Post a Comment